OncoMatch/Clinical Trials/NCT04951947
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
Is NCT04951947 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies JS201 combine with Lenvatinib for small-cell lung cancer.
Treatment: JS201 combine with Lenvatinib — This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w, lenvatinib 8mg po. Qd.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: EC plus anti-PD-L1 therapy — first-line
The patient failed first-line EC+PD-L1 treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify